anti cd8a monoclonal antibody Search Results


mab recognizing cd8a  (Bio X Cell)
94
Bio X Cell mab recognizing cd8a
Fig. 6 Suppression of CTLs by CD11b+ MDSCs is responsible for the acceleration of tumor progression by Regnase-1 downregulation. A-D Evaluation of phenotypes of orthotopic syngeneic tumors of WT or Regnase-1 KO murine pancreatic cancer cells. Representative macro images of pancreatic tumors (A). Relative mRNA levels of <t>Cd8a,</t> Ifng, Fasl, and Gzmb (B) (N = 6 per group). Representative images of HE (C, left panel) and CD8a immunostaining (C, right panel) and the number of CD8-positive cells (C, right) (N = 6 per group). Dot plots of CD3+CD8+ cells evaluated by flow cytometry (D, left) and the proportion of CD8 + cells among CD45+ cells (D, right) (N = 3 per group). E–H Evaluation of phenotypes of orthotopic syngeneic tumors of WT or Regnase-1-KO murine pancreatic cancer cells with or without depletion of CD8+ cells upon anti-CD8a antibody or IgG treatment. Experimental schematic (E). Dot plots of CD3+ and CD8.+ cells in WT or Regnase-1-KO syngeneic tumors upon anti-CD8a antibody or IgG treatment evaluated by flow cytometry (F). Tumor weights (G) (N = 6 per group). The relative mRNA levels of Cd8a, Ifng, Fasl, and Gzmb (H) (N = 6 per group). Student’s t test was used to evaluate differences between 2 groups. One-way ANOVA with Tukey’s post hoc test was used to compare differences among 4 groups. *P < 0.05, scale bars: 100 μm (insets)
Mab Recognizing Cd8a, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+cd8a+monoclonal+antibody/pm37814340-61-4-13?v=Bio+X+Cell
Average 94 stars, based on 1 article reviews
mab recognizing cd8a - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier
fluorescein-labelled monoclonal rat anti-mouse cd8a antibody  (SERVA Electrophoresis)
90
SERVA Electrophoresis fluorescein-labelled monoclonal rat anti-mouse cd8a antibody
Fig. 6 Suppression of CTLs by CD11b+ MDSCs is responsible for the acceleration of tumor progression by Regnase-1 downregulation. A-D Evaluation of phenotypes of orthotopic syngeneic tumors of WT or Regnase-1 KO murine pancreatic cancer cells. Representative macro images of pancreatic tumors (A). Relative mRNA levels of <t>Cd8a,</t> Ifng, Fasl, and Gzmb (B) (N = 6 per group). Representative images of HE (C, left panel) and CD8a immunostaining (C, right panel) and the number of CD8-positive cells (C, right) (N = 6 per group). Dot plots of CD3+CD8+ cells evaluated by flow cytometry (D, left) and the proportion of CD8 + cells among CD45+ cells (D, right) (N = 3 per group). E–H Evaluation of phenotypes of orthotopic syngeneic tumors of WT or Regnase-1-KO murine pancreatic cancer cells with or without depletion of CD8+ cells upon anti-CD8a antibody or IgG treatment. Experimental schematic (E). Dot plots of CD3+ and CD8.+ cells in WT or Regnase-1-KO syngeneic tumors upon anti-CD8a antibody or IgG treatment evaluated by flow cytometry (F). Tumor weights (G) (N = 6 per group). The relative mRNA levels of Cd8a, Ifng, Fasl, and Gzmb (H) (N = 6 per group). Student’s t test was used to evaluate differences between 2 groups. One-way ANOVA with Tukey’s post hoc test was used to compare differences among 4 groups. *P < 0.05, scale bars: 100 μm (insets)
Fluorescein Labelled Monoclonal Rat Anti Mouse Cd8a Antibody, supplied by SERVA Electrophoresis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+cd8a+monoclonal+antibody/pm15335726-39-19-25?v=SERVA+Electrophoresis
Average 90 stars, based on 1 article reviews
fluorescein-labelled monoclonal rat anti-mouse cd8a antibody - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
mouse anti- cd8a monoclonal antibody  (Cusabio)
N/A
Mouse anti-Human CD8A Monoclonal Antibody
   Buy from Supplier
anti-human cd8 cd8a monoclonal antibody mfluor540 conjugated, flow validated  (Boster Bio)
N/A
Boster Bio Anti-Human CD8 Cd8a Monoclonal Antibody mFluor540 Conjugated, Flow Validated (Catalog# FC02236-mFluor540). Tested in Flow Cytometry application(s). This antibody reacts with Human.
   Buy from Supplier
anti-ms cd8a purified monoclonal antibody  (Boster Bio)
N/A
Boster Bio Anti-Ms CD8a Purified Monoclonal Antibody (Catalog# M02236). Tested in Flow Cytometry, IP, IHC-P, IHC-F, ICC application(s). This antibody reacts with Mouse.
   Buy from Supplier
anti-cd8a monoclonal antibody, clone zut270.5  (Creative BioMart)
N/A
Identifies cytotoxic/suppressor T-cells that interact with MHC class I bearing targets. CD8 is thought to play a role in the process of T-cell mediated killing. CD8 alpha chains binds to class I MHC molecules alpha-3
   Buy from Supplier
rat monoclonal anti-mouse cd8a antibody  (Angio-Proteomie)
N/A
   Buy from Supplier
anti-cd8a monoclonal antibody, clone gf2.21f0  (Creative BioMart)
N/A
This antibody recognises the feline homologue of CD8 alpha and detects a broad band between 28-32kD by immunoprecipitation.Identifies cytotoxic/suppressor T-cells that interact with MHC class I bearing targets. CD8 is thought to play a role
   Buy from Supplier
anti-human cd8 cd8a monoclonal antibody apc conjugated, flow validated  (Boster Bio)
N/A
Boster Bio Anti-human CD8 Cd8a Monoclonal Antibody APC Conjugated, Flow Validated (Catalog# FC02236-APC). Tested in Flow Cytometry application(s). This antibody reacts with Human.
   Buy from Supplier
mouse monoclonal anti-rat cd8a antibody  (Angio-Proteomie)
N/A
   Buy from Supplier
anti-human cd8 cd8a monoclonal antibody percp conjugated, flow validated  (Boster Bio)
N/A
Boster Bio Anti-human CD8 Cd8a Monoclonal Antibody PerCP Conjugated, Flow Validated (Catalog# FC02236-PerCP). Tested in Flow Cytometry application(s). This antibody reacts with Human.
   Buy from Supplier

Image Search Results


Fig. 6 Suppression of CTLs by CD11b+ MDSCs is responsible for the acceleration of tumor progression by Regnase-1 downregulation. A-D Evaluation of phenotypes of orthotopic syngeneic tumors of WT or Regnase-1 KO murine pancreatic cancer cells. Representative macro images of pancreatic tumors (A). Relative mRNA levels of Cd8a, Ifng, Fasl, and Gzmb (B) (N = 6 per group). Representative images of HE (C, left panel) and CD8a immunostaining (C, right panel) and the number of CD8-positive cells (C, right) (N = 6 per group). Dot plots of CD3+CD8+ cells evaluated by flow cytometry (D, left) and the proportion of CD8 + cells among CD45+ cells (D, right) (N = 3 per group). E–H Evaluation of phenotypes of orthotopic syngeneic tumors of WT or Regnase-1-KO murine pancreatic cancer cells with or without depletion of CD8+ cells upon anti-CD8a antibody or IgG treatment. Experimental schematic (E). Dot plots of CD3+ and CD8.+ cells in WT or Regnase-1-KO syngeneic tumors upon anti-CD8a antibody or IgG treatment evaluated by flow cytometry (F). Tumor weights (G) (N = 6 per group). The relative mRNA levels of Cd8a, Ifng, Fasl, and Gzmb (H) (N = 6 per group). Student’s t test was used to evaluate differences between 2 groups. One-way ANOVA with Tukey’s post hoc test was used to compare differences among 4 groups. *P < 0.05, scale bars: 100 μm (insets)

Journal: Journal of experimental & clinical cancer research : CR

Article Title: Regnase-1 downregulation promotes pancreatic cancer through myeloid-derived suppressor cell-mediated evasion of anticancer immunity.

doi: 10.1186/s13046-023-02831-w

Figure Lengend Snippet: Fig. 6 Suppression of CTLs by CD11b+ MDSCs is responsible for the acceleration of tumor progression by Regnase-1 downregulation. A-D Evaluation of phenotypes of orthotopic syngeneic tumors of WT or Regnase-1 KO murine pancreatic cancer cells. Representative macro images of pancreatic tumors (A). Relative mRNA levels of Cd8a, Ifng, Fasl, and Gzmb (B) (N = 6 per group). Representative images of HE (C, left panel) and CD8a immunostaining (C, right panel) and the number of CD8-positive cells (C, right) (N = 6 per group). Dot plots of CD3+CD8+ cells evaluated by flow cytometry (D, left) and the proportion of CD8 + cells among CD45+ cells (D, right) (N = 3 per group). E–H Evaluation of phenotypes of orthotopic syngeneic tumors of WT or Regnase-1-KO murine pancreatic cancer cells with or without depletion of CD8+ cells upon anti-CD8a antibody or IgG treatment. Experimental schematic (E). Dot plots of CD3+ and CD8.+ cells in WT or Regnase-1-KO syngeneic tumors upon anti-CD8a antibody or IgG treatment evaluated by flow cytometry (F). Tumor weights (G) (N = 6 per group). The relative mRNA levels of Cd8a, Ifng, Fasl, and Gzmb (H) (N = 6 per group). Student’s t test was used to evaluate differences between 2 groups. One-way ANOVA with Tukey’s post hoc test was used to compare differences among 4 groups. *P < 0.05, scale bars: 100 μm (insets)

Article Snippet: BE0061, a fully neutralizing mAb recognizing CD8a, and control IgG were obtained from Bioxcell.

Techniques: Immunostaining, Flow Cytometry